For patients with extremely high cholesterol, the promise of new PCSK9 inhibitors just keeps growing. Data presented at this month’s American Heart Association meeting confirms that the breakthrough drugs lower LDL cholesterol – as anticipated. But it also reveals that the treatments can reduce the buildup of heart attack-causing plaque on the walls of coronary arteries.
Now the study’s results beg the question: Will new evidence of PCSK9 inhibitors’ impact lead to improved health plan coverage?
More at Institute for Patient Access